Casdin Capital operates as a hybrid crossover platform that invests across the entire lifecycle of life sciences companies from seed through post-IPO, combining both public equity and private portfolio strategies with deep scientific expertise including a Chief Medical Officer and PhD scientific advisors. The firm positions itself at the crossroads of genomics, data and capital by backing information platforms that process and analyze molecular data to unlock biological insights, rather than traditional biotech therapeutics, with a portfolio heavily weighted toward transformational genomics and synthetic biology companies like 23andMe, Ginkgo Bioworks, and Recursion.